Various serological tests described in the literature use different isocyanate-albumin conjugates preparations to detect immunological responses. Published data obtained using HDI and TDI conjugates generated with their vapor phase suggest that there may be antigenic differences (in-vapor phase generated isocyanate-albumin conjugates

versus in-solution phase) related to the biophysics of the conjugation reaction (Wisnewski et al. 2004; Wisnewski 2007). Furthermore, it was considered that vapor phase exposure would lead to limited isocyanate conjugation with albumin, which presumably reflects the pathophysiological

Compound C nmr conditions during occupational exposure to isocyanates (Wisnewski 2007). The importance of these findings should not be underestimated when combining the serological test results with well-defined clinical data for future diagnosis and preventive measures with asthma. Unfortunately, relatively few publications provide all necessary individual diagnostic ARN-509 concentration parameters with the relevant immunological data, precluding comparisons with clinical diagnosis (Wisnewski and Jones 2010). Frequently, either the data on antibody assays (in-house assay used in most studies) or the clinical information for the individual patients is lacking (i.e. only positive SIC is provided as indicator for isocyanate asthma), or it remains unclear how the dose response and the detection limits (LODs) were calculated (and if the available analytical standards were used), making useful Chlormezanone comparisons between the clinical parameters and the serological data difficult. Since clinical examinations including lung function tests are often

insufficient for reliable isocyanate asthma diagnosis and the available immunological tests identify only a proportion of the affected subjects, there is a need for improvement and standardization of existing diagnostic tests. In an attempt to evaluate how the isocyanate conjugates influence the diagnostic sensitivity of the specific IgE immuno-fluorescence assay, we have adopted the existing methods to prepare MDI-HSA (human serum albumin) conjugates in-vapor and could observe a significant increase in the assay sensitivity as compared to the conjugates prepared in-solution.